Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Wednesday, August 24, 2011

Pharmasset receives fast track designation for Hep C drug PSI-938

PSI-938 inhibits the Hep C virus, as the drug's composition is similar enough to the structural make up of genetic molecules, allowing it to be easily incorporated into a growing strand of DNA. From there, it acts as a chain terminator, stopping the viral DNA from reproducing.

In March, Pharmasset presented the results of a 14-day study of PSI-938, which revealed strong anti-viral activity and safety and tolerability, both as a stand-alone treatment as well as in combination with the company's PSI-7977, also an inhibitor of viral DNA.

Read more.....

No comments:

Post a Comment